By suppressing programmed cell death-1 (PD-1), programmed death ligand 1 (PD-L1), and cytotoxic T-lymphocyte antigen-4 (CTLA-4) receptors, ICIs enhance the immune response against cancer cells [1]. This evidence concerns the gene PDCD1 and cancer.